We demonstrated that SFN effectively potentiated adaptive cellular therapy responses against tumor cells by inhibiting the PD-1/PD-L1 pathway, which indicated that SFN exhibited double benefits with CAR-T cells in mediating tumor regression. Here, CD274 is linked to neoplasm.